Rinvoq Approved in EU for Two Types of Active Arthritis

Rinvoq Approved in EU for Two Types of Active Arthritis

284773

Rinvoq Approved in EU for Two Types of Active Arthritis

AbbVie‘s Rinvoq (upadacitinib) has been approved in the European Union to treat active ankylosing spondylitis (AS) in adults who have responded inadequately to conventional therapy. The European Commission also approved Rinvoq to treat active psoriatic arthritis (PsA) in adults who have not responded to, or are intolerant of, standard therapies. These approvals, which follow a positive recommendation from the Committee for Medicinal Products for Human Use (part of the European Medicines Agency), cover all member…

You must be logged in to read/download the full post.